AstraZeneca Announces KALOS, LOGOS Trials Met All Primary Endpoints
AstraZeneca's Fixed-Dose Triple-Combination Therapy BREZTRI AEROSPHERE Meets Primary Endpoints In KALOS And LOGOS Phase III Trials In Asthma
AstraZeneca Reported High-level Results From The Phase 3 KALOS and LOGOS Trials, Showing Fixed-dose Triple-combination Therapy Breztri Aerosphere Met All Primary Endpoints In Patients With Uncontrolled Asthma
AstraZeneca's Asthma Drug Improves Lung Function in Late-stage Studies
AstraZeneca Director Invests in Company Shares
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
AstraZeneca Announces Current Voting Rights and Share Capital Structure
FDA to Tighten Vaccine Approval Requirements: Reports
Trump Administration Said to Be Investing $500M on Developing Universal Vaccines
Goldman Sachs Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca Price Target Lowered to 13,700 GBp at Morgan Stanley
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca Plc
AstraZeneca Considering Moving More Production to U.S., Pharmaphorum Reports
Deutsche Bank Reaffirms Their Hold Rating on AstraZeneca (AZN)
AstraZeneca's Truqap Fails in Another Phase III Trial
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating
AstraZeneca's Strong EPS Performance and Strategic Developments Justify Buy Rating
BofA Securities Keeps AstraZeneca at Buy as Q1 EPS Tops Consensus
AstraZeneca's Earnings Call: Strong Growth Amid Challenges